Multiple Drug Use Clinical Trial
Official title:
Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention
Verified date | May 2024 |
Source | Texas Tech University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The proposed study will examine brain mechanisms of a brief mindfulness intervention - integrative body-mind training (IBMT) on alcohol, tobacco, and cannabis (ATC) reduction.
Status | Completed |
Enrollment | 70 |
Est. completion date | February 28, 2023 |
Est. primary completion date | February 28, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 23 Years |
Eligibility | Inclusion Criteria: - (1) at least 18 years old; - (2) free of any psychiatric diagnoses or medication (besides a substance use disorder to alcohol, tobacco, or cannabis); - (3) in the past month, at least 4 episode of heavy episodic drinking; at least 3 occasion of cannabis use; and daily cigarette use for at least the past month; - (4) normal or corrected-to-normal vision; - (5) written informed consent; - (6) no previous meditation or neurofeedback (NF) experiences. Exclusion Criteria: - (1) any psychiatric diagnoses other than a substance use disorder; - (2) medical disorder(s) that may affect the central nervous system; medications that affect the central and autonomic nervous system; or a positive pregnancy test result (females); - (3) excluding cannabis, evidence of recent (past month) illicit drug use. |
Country | Name | City | State |
---|---|---|---|
United States | TTU/UT | Lubbock | Texas |
Lead Sponsor | Collaborator |
---|---|
Texas Tech University | National Center for Complementary and Integrative Health (NCCIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Brain Changes in Functional Activity | 70 participants with polysubstance use are assessed by changes of brain in functional activity of anterior cingulate cortex before (baseline) and post-intervention (2 weeks). | The outcome measure is assessed at baseline and post-intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06214130 -
Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets
|
Phase 1 | |
Recruiting |
NCT06324786 -
Brain Mechanisms of Reducing Polysubstance Use
|
N/A | |
Completed |
NCT01689493 -
Strategy to Improve Antiplatelet Therapy Adherence After Coronary Stent Implantation
|
N/A | |
Recruiting |
NCT01758679 -
A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma
|
Phase 4 |